Appetite for allergies: Alladapt banks $119M to push immunotherapy through trials June 22, 2022 6:03 am https://www.fiercebiotech.com/biotech/appetite-allergies-alladapt-banks-119m-push-immunotherapy-through-trials

Beacon of Hope: Novartis commits $17.7M to set up clinical trial centers in historically Black medical schools June 22, 2022 4:57 am https://www.fiercebiotech.com/biotech/beacon-hope-novartis-commits-177m-set-clinical-trial-centers-historically-black-medical

Frying pan, meet fire: Athira flunks Alzheimer’s trial to pile on the pain ahead of phase 3 data drop June 22, 2022 2:57 am https://www.fiercebiotech.com/biotech/frying-pan-meet-fire-athira-flunks-alzheimers-trial-pile-pain-ahead-phase-3-data-drop

Novartis plots Precision attack on sickle cell, paying $75M and putting up $1.4B in biobucks to form in vivo gene editing pact June 21, 2022 11:41 pm https://www.fiercebiotech.com/biotech/novartis-plots-precision-attack-sickle-cell-paying-50m-and-putting-14b-biobucks-form-vivo

CRISPR Tx's Innovation Day dragged down by multiple myeloma replacement, lackluster results in kidney cancer June 21, 2022 7:37 pm https://www.fiercebiotech.com/biotech/crispr-distances-itself-multiple-myeloma-candidate-sees-stock-fall-amid-innovation-day

Galapagos finally takes M&A plunge, spending $251M for 2 biotechs in CAR-T push June 21, 2022 4:57 pm https://www.fiercebiotech.com/biotech/galapagos-finally-takes-ma-plunge-spending-251m-car-t-push

9 Meters’ celiac drug doesn’t measure up in phase 3 June 21, 2022 9:20 am https://www.fiercebiotech.com/biotech/9-meters-celiac-drug-doesnt-measure-biotech-may-pull-trial-after-phase-3-flop

Merck's next-gen pneumococcal vaccine slated for July phase 3 after two-part win June 21, 2022 4:02 am https://www.fiercebiotech.com/biotech/merck-co-readies-next-gen-pneumococcal-vaccine-phase-3-july-after-positive-results

Lyme-light: Pfizer triggers surge in Valneva’s stock with €91M investment to support phase 3 vaccine trial June 21, 2022 3:40 am https://www.fiercebiotech.com/biotech/lyme-light-pfizer-triggers-surge-valnevas-stock-eu91m-investment-support-phase-3-vaccine

Hot on Alnylam’s heels, AstraZeneca racks up phase 3 win for Ionis-partnered rare disease drug June 21, 2022 1:43 am https://www.fiercebiotech.com/biotech/hot-alnylams-heels-astrazeneca-racks-phase-3-win-ionis-partnered-rare-disease-drug